News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

Long-term dupilumab blocks relapse in moderate-to-severe atopic dermatitis
25 May 2026
byStephen Padilla
The use of dupilumab significantly delays disease relapse in patients with moderate-to-severe atopic dermatitis (AD) while having an acceptable safety profile, reports a study.
Long-term dupilumab blocks relapse in moderate-to-severe atopic dermatitis
25 May 2026
Early antiviral treatment helps reduce risk of long COVID
23 May 2026
byJairia Dela Cruz
Individuals with acute COVID-19 who receive prompt antiviral treatment, such as ensitrelvir, nirmatrelvir, or molnupiravir, in the outpatient setting may be less likely to experience post–COVID-19 condition (PCC) compared with those who receive no treatment.







